Bharat Immunological and Biologicals Corporation is a government-owned biotechnology business that was founded in 1989. The company produces BIB Sweet Tablets, Zinc Tablets, Oral Polio Vaccine, and Diarrhea Management Kits. Bharat Biotech International Limited was founded by Dr. Krishna Ella in 1996, and he currently serves as its executive chairman.
Bharat Biotech – Quick Overview
| Particular | Details |
| Company Name | Bharat Biotech International Limited (BBIL) |
| Type | Private Biotechnology / Pharmaceutical Company |
| Industry | Biotechnology, Vaccine & Biotherapeutics Manufacturing |
| Founded | 1996 |
| Founders | Dr. Krishna M. Ella & Mrs. Suchitra K. Ella |
| Headquarters | Genome Valley, Turakapally, Hyderabad, Telangana, India |
| Managing Director / Key People | Dr. Krishna M. Ella (Chairman & MD) |
| Core Business | Research, development & manufacturing of vaccines & bio-therapeutics |
| Major Products | ROTAVAC, Typbar TCV, Biopolio, Comvac, JENVAC, COVAXIN & others |
| Global Presence | Vaccines in 125+ countries, global exports & registrations |
| Patents & R&D | Over 220 global patents, extensive R&D in vaccines & biologics |
| Manufacturing Approvals | Facilities approved by USFDA, WHO, KFDA quality standards |
| Notable Innovation | World’s first WHO-prequalified Typhoid Conjugate Vaccine; oral cholera vaccine development |
| Area Served | Worldwide (developing & global markets) |
| Strategic Focus | Affordable, high-quality vaccines & bio-therapeutics for public health |
| Official Website | bharatbiotech.com |
Net Worth and Market Cap
With a market capitalization of 73.8 crore, the net worth exceeds Rs 244.4 crore.
Corporate Leadership
Bharat Immunological and Biologicals Corporation is a government-owned biotechnology business that was founded in 1989. The company’s chairman and MD is Dr. Krishna Ella.
Overview of Services
Based in Hyderabad, India, Bharat Biotech International Limited (BBIL) is a worldwide biotechnology firm that produces medicines, biotherapeutics, vaccines, and healthcare items in addition to conducting drug development and discovery.
Scale of Operations
The production plant of Bharat Biotech is located in Hyderabad, India’s Genome Valley. The company employs more than 700 people and is present all over the world as of July 2020.
The company is situated in Distt. Bulandshahar (UP) has a 50-acre total land area. The infrastructure of the company includes water plants, GMP-certified pharmaceutical labs, vaccine labs, and other utility services.
The firm is in charge of creating ROTAVAC, a naturally attenuated strain-derived rotavirus vaccine and an environmentally friendly recombinant. They were among the first to create vaccinations against viral illnesses like Zika and Chikungunya. Additionally, the business manufactures vaccinations against rabies, influenza H1N1, and Japanese encephalitis. Biosafety level 3 (BSL3) labs are available at Bharat Biotech.
It has created the first conjugated tetanus-toxoid vaccination for typhoid in history. As of May 2025, Bharat Biotech has provided more than nine billion doses of vaccines worldwide, held more than 145 patents worldwide, and had over 19 vaccines, four biotherapeutics, and registrations in more than 125 countries.
With two studies underway—the oral cholera vaccine and plasma-derived medicines—the company is expanding. Additionally, the company received approval for the Covaxin Project.
